Journal of Cardiovascular Pharmacology

AUGUST 6, 2024

Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload. Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload.

Heart Failure 40

Heart Failure Hospital Article 40

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Pharmacology Diabetes 40

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Pharmacology 45

Journal of Cardiovascular Pharmacology

NOVEMBER 16, 2023

ABSTRACT: Management of heart failure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms. The primary objective was to evaluate the association of serum albumin level with urine output (UOP) in hospitalized HF patients who received concomitant albumin and loop diuretic therapy. 95% CI -1558.6,

Heart Failure 40

Heart Failure ICU Hospital Article 40

Open Heart

JULY 28, 2023

Introduction The incidence of arrhythmia in heart failure with non-reduced ejection fraction (HFnon-rEF) in patients who have a history of hospitalisation is unclear.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Heart Failure Tachycardia 40

Journal of Cardiovascular Pharmacology

NOVEMBER 14, 2023

Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF). There were 551 events (10.36%) of hospitalization for HF in the SGLT2i group, compared to 751 (14.11%) in the placebo group with an HR of 0.71, 95% CI of 0.62 to 0.86 (p<0.0001). to 0.81 (p<0.0001).

Heart Failure 40

Heart Failure Outcomes Hospital Diabetes 40

DAIC

DECEMBER 12, 2023

Wang’s research lab, which recently relocated to USF from Harvard Medical School where he was a professor working at Boston Children’s Hospital. Major damage from injury to the heart, often as a result of a severe heart attack, can lead to heart failure because the heart is no longer able to contract normally.

Heart Attack 105

Heart Attack Heart attacks Heart Disease Pharmacology 105

DAIC

DECEMBER 22, 2023

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

Tricuspid 59

Tricuspid Pacemaker Heart Valves Open-Heart Surgery 59

Journal of Cardiovascular Pharmacology

APRIL 9, 2024

Abstract: Recent studies have revealed the benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure patients. Patients treated with SGLT2i exhibited a significantly lower rate of hospitalization for heart failure (HF) (OR=0.50, 95%CI: 0.32-0.80) 0.80) and all-cause death (OR=0.65, 95%CI: 0.44–0.95)

Myocardial Infarction 40

Myocardial Infarction Diabetes Heart Failure Hospital 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Journal of Cardiovascular Pharmacology

NOVEMBER 11, 2024

Patients with ST-segment elevation myocardial infarction (STEMI) and complex coronary artery disease (CAD) face a poor prognosis, including increased heart failure (HF) risk. All three CAD complexity scores (SYNTAX, SYNTAX II and Gensini) were associated with an increased risk of adverse events (HR 1.02 to 1.06, all p-values ≤0.025).

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction STEMI Heart Failure 40

Dr. Smith's ECG Blog

APRIL 8, 2016

Crit Care Med 1991; 19:694) Concentrated Potassium Chloride Infusions in Critically Ill Patients with Hypokalemia The Journal of Clinical Pharmacology. Thus, hypokalemia is prevalent immediately after out-of-hospital cardiac arrest, whereas it is uncommon in AMI in the absence of cardiac arrest. However, the mean level (2.50.4

STEMI 52

STEMI Myocardial Infarction Cardiac Arrest Arrhythmia 52

Dr. Smith's ECG Blog

NOVEMBER 19, 2016

Author continued : STE in aVR is often due to left main coronary artery obstruction (OR 4.72), and is associated with in-hospital cardiovascular mortality (OR 5.58). In cardiogenic shock, fluid may worsen the pulmonary edema associated with acute heart failure, but may still be required to support the hemodynamic status of the patient.

Ischemia 40

Ischemia Cardiogenic Shock Aortic Stenosis 40